{"pmid":32406001,"pmcid":"PMC7220846","title":"COVID-19 with rheumatic diseases: a report of 5 cases.","text":["COVID-19 with rheumatic diseases: a report of 5 cases.","The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidly progress into severe COVID-19. In this case report, we describe the clinical features of 5 rheumatic immune disease patients with the concomitant presence of COVID-19. Amongst these patients, 4 had rheumatoid arthritis (RA) and 1 had systemic sclerosis (SSc). Two patients had a history of close contact with a COVID-19 patient. The age of the patients ranged between 51 and 79 years. Fever (80%), cough (80%), dyspnea (40%), and fatigue (20%) were the most common presenting symptoms. Laboratory investigations revealed leukopenia and lymphopenia in 2 patients. In all the patients, chest computerized tomography (CT) revealed patchy ground glass opacities in the lungs. During the hospital stay, the condition of two patients remained the same (i.e., mild COVID-19), two patients progressed to the severe COVID-19, and one patient worsened to the critically ill COVID-19. These patients were treated with antiviral agents for COVID-19, antibiotics for secondary bacterial infections, and immunomodulatory agents for rheumatic immune diseases. All the patients responded well, were cured of COVID-19, and subsequently discharged.","Clin Rheumatol","Cheng, Chuanfang","Li, Chuanjing","Zhao, Tao","Yue, Jing","Yang, Fang","Yan, Yimin","Liu, Xiaoan","32406001"],"abstract":["The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidly progress into severe COVID-19. In this case report, we describe the clinical features of 5 rheumatic immune disease patients with the concomitant presence of COVID-19. Amongst these patients, 4 had rheumatoid arthritis (RA) and 1 had systemic sclerosis (SSc). Two patients had a history of close contact with a COVID-19 patient. The age of the patients ranged between 51 and 79 years. Fever (80%), cough (80%), dyspnea (40%), and fatigue (20%) were the most common presenting symptoms. Laboratory investigations revealed leukopenia and lymphopenia in 2 patients. In all the patients, chest computerized tomography (CT) revealed patchy ground glass opacities in the lungs. During the hospital stay, the condition of two patients remained the same (i.e., mild COVID-19), two patients progressed to the severe COVID-19, and one patient worsened to the critically ill COVID-19. These patients were treated with antiviral agents for COVID-19, antibiotics for secondary bacterial infections, and immunomodulatory agents for rheumatic immune diseases. All the patients responded well, were cured of COVID-19, and subsequently discharged."],"journal":"Clin Rheumatol","authors":["Cheng, Chuanfang","Li, Chuanjing","Zhao, Tao","Yue, Jing","Yang, Fang","Yan, Yimin","Liu, Xiaoan"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32406001","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s10067-020-05160-x","keywords":["covid-19","coronavirus","rheumatic immune disease","sars-cov-2"],"topics":["Case Report"],"weight":1,"_version_":1666950579837992960,"score":9.490897,"similar":[{"pmid":32240718,"pmcid":"PMC7118604","title":"COVID-19 in Hemodialysis Patients: A Report of 5 Cases.","text":["COVID-19 in Hemodialysis Patients: A Report of 5 Cases.","In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in China and spread rapidly worldwide. It is unknown whether hemodialysis patients represent a distinct group of patients with certain characteristics that may make them susceptible to infection or severe disease. In this case report, we describe the clinical and epidemiologic features of COVID-19 infection in 201 maintenance hemodialysis patients in Zhongnan Hospital of Wuhan University, including 5 maintenance hemodialysis patients who contracted COVID-19 infection. Of the 5 patients with COVID-19 infection, one had a definite history of contact with an infected person. The age range of the patients was 47 to 67 years. Diarrhea (80%), fever (60%), and fatigue (60%) were the most common symptoms. Lymphopenia occurred in all patients. Computed tomography of the chest showed ground glass opacity in the lungs of all patients. Up to February 13, 2020, none of the patients had developed severe complications (acute respiratory distress syndrome, shock, or multiple organ dysfunction) or died.","Am J Kidney Dis","Wang, Rui","Liao, Cong","He, Hong","Hu, Chun","Wei, Zimeng","Hong, Zixi","Zhang, Chengjie","Liao, Meiyan","Shui, Hua","32240718"],"abstract":["In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in China and spread rapidly worldwide. It is unknown whether hemodialysis patients represent a distinct group of patients with certain characteristics that may make them susceptible to infection or severe disease. In this case report, we describe the clinical and epidemiologic features of COVID-19 infection in 201 maintenance hemodialysis patients in Zhongnan Hospital of Wuhan University, including 5 maintenance hemodialysis patients who contracted COVID-19 infection. Of the 5 patients with COVID-19 infection, one had a definite history of contact with an infected person. The age range of the patients was 47 to 67 years. Diarrhea (80%), fever (60%), and fatigue (60%) were the most common symptoms. Lymphopenia occurred in all patients. Computed tomography of the chest showed ground glass opacity in the lungs of all patients. Up to February 13, 2020, none of the patients had developed severe complications (acute respiratory distress syndrome, shock, or multiple organ dysfunction) or died."],"journal":"Am J Kidney Dis","authors":["Wang, Rui","Liao, Cong","He, Hong","Hu, Chun","Wei, Zimeng","Hong, Zixi","Zhang, Chengjie","Liao, Meiyan","Shui, Hua"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240718","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1053/j.ajkd.2020.03.009","keywords":["covid-19","hemodialysis","sars-cov-2","case report","chest radiograph","coronavirus","diarrhea","end-stage renal disease (esrd)","symptoms"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138490259111936,"score":229.77634},{"pmid":32444415,"title":"Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China.","text":["Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China.","OBJECTIVE: The clinical features of rheumatic patients with coronavirus disease 2019 (COVID-19) have not been reported. This study aimed to describe the clinical features of COVID-19 in rheumatic patients and provide information for handling this situation in clinical practice. METHODS: This is a retrospective case series study. Deidentified data, including gender, age, laboratory and radiological results, symptoms, signs, and medication history, were collected from 2326 patients diagnosed with COVID-19, including 21 cases in combination with rheumatic disease, in Tongji Hospital between 13 January and 15 March 2020. RESULTS: Length of hospital stay and mortality rate were similar between rheumatic and non-rheumatic groups, while the presence of respiratory failure was more common in rheumatic cases (38% vs 10%, p<0.001). Symptoms of fever, fatigue and diarrhoea were seen in 76%, 43% and 23% of patients, respectively. There were four rheumatic patients who experienced a flare of rheumatic disease during hospital stay, with symptoms of muscle aches, back pain, joint pain or rash. While lymphocytopaenia was seen in 57% of rheumatic patients, only one patient (5%) presented with leucopenia in rheumatic cases. Rheumatic patients presented with similar radiological features of ground-glass opacity and consolidation. Patients with pre-existing interstitial lung disease showed massive fibrous stripes and crazy-paving signs at an early stage. Five rheumatic cases used hydroxychloroquine before the diagnosis of COVID-19 and none progressed to critically ill stage. CONCLUSIONS: Respiratory failure was more common in rheumatic patients infected with COVID-19. Differential diagnosis between COVID-19 and a flare of rheumatic disease should be considered. TRIAL REGISTRATION NUMBER: ChiCTR2000030795.","Ann Rheum Dis","Ye, Cong","Cai, Shaozhe","Shen, Guifen","Guan, Hanxiong","Zhou, Liling","Hu, Yangyang","Tu, Wei","Chen, Yu","Yu, Yikai","Wu, Xuefen","Chen, Yuxue","Zhong, Jixin","Dong, Lingli","32444415"],"abstract":["OBJECTIVE: The clinical features of rheumatic patients with coronavirus disease 2019 (COVID-19) have not been reported. This study aimed to describe the clinical features of COVID-19 in rheumatic patients and provide information for handling this situation in clinical practice. METHODS: This is a retrospective case series study. Deidentified data, including gender, age, laboratory and radiological results, symptoms, signs, and medication history, were collected from 2326 patients diagnosed with COVID-19, including 21 cases in combination with rheumatic disease, in Tongji Hospital between 13 January and 15 March 2020. RESULTS: Length of hospital stay and mortality rate were similar between rheumatic and non-rheumatic groups, while the presence of respiratory failure was more common in rheumatic cases (38% vs 10%, p<0.001). Symptoms of fever, fatigue and diarrhoea were seen in 76%, 43% and 23% of patients, respectively. There were four rheumatic patients who experienced a flare of rheumatic disease during hospital stay, with symptoms of muscle aches, back pain, joint pain or rash. While lymphocytopaenia was seen in 57% of rheumatic patients, only one patient (5%) presented with leucopenia in rheumatic cases. Rheumatic patients presented with similar radiological features of ground-glass opacity and consolidation. Patients with pre-existing interstitial lung disease showed massive fibrous stripes and crazy-paving signs at an early stage. Five rheumatic cases used hydroxychloroquine before the diagnosis of COVID-19 and none progressed to critically ill stage. CONCLUSIONS: Respiratory failure was more common in rheumatic patients infected with COVID-19. Differential diagnosis between COVID-19 and a flare of rheumatic disease should be considered. TRIAL REGISTRATION NUMBER: ChiCTR2000030795."],"journal":"Ann Rheum Dis","authors":["Ye, Cong","Cai, Shaozhe","Shen, Guifen","Guan, Hanxiong","Zhou, Liling","Hu, Yangyang","Tu, Wei","Chen, Yu","Yu, Yikai","Wu, Xuefen","Chen, Yuxue","Zhong, Jixin","Dong, Lingli"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32444415","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/annrheumdis-2020-217627","keywords":["autoimmune diseases","autoimmunity","inflammation"],"locations":["Tongji Hospital","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine"],"topics":["Diagnosis"],"weight":1,"_version_":1667600475842674689,"score":208.59793},{"pmid":32311836,"title":"Experiences of Patients with Rheumatic Diseases in the US During Early Days of the COVID-19 Pandemic.","text":["Experiences of Patients with Rheumatic Diseases in the US During Early Days of the COVID-19 Pandemic.","OBJECTIVE: Patients with rheumatic diseases such as rheumatoid arthritis (RA) and lupus have increased risk of infection and are treated with medications that may increase this risk yet are also hypothesized to help treat COVID-19. We set out to understand how the COVID-19 pandemic has impacted the lives of these patients in the US. METHODS: Participants in a US-wide longitudinal observational registry responded to a supplemental COVID-19 questionnaire by email on March 25, 2020 about their symptoms, COVID-19 testing, healthcare changes, and related experiences during the prior two weeks. Analysis compared responses by diagnosis, disease activity, and new onset of symptoms. Qualitative analysis was conducted on optional free-text comment fields. RESULTS: Of the 7,061 participants invited, 530 responded, with RA the most frequent diagnosis (61%). Eleven met COVID-19 screening criteria, of which two sought testing unsuccessfully. Six others sought testing, three were successful, and all were negative. Not quite half (42%) reported a change to their care in the prior two weeks. Qualitative analysis revealed four key themes: emotions in response to the pandemic, perceptions of risks from immunosuppressive medications, protective measures to reduce risk of COVID-19 infection, and disruptions in accessing rheumatic disease medications including hydroxychloroquine. CONCLUSION: After two weeks, many with rheumatic diseases already had important changes to their healthcare, with many altering medications without professional consultation or due to hydroxychloroquine shortage. As evidence accumulates on the effectiveness of potential COVID-19 treatments, effort is needed to safeguard access to established treatments for rheumatic diseases.","ACR Open Rheumatol","Michaud, Kaleb","Wipfler, Kristin","Shaw, Yomei","Simon, Teresa A","Cornish, Adam","England, Bryant R","Ogdie, Alexis","Katz, Patricia","32311836"],"abstract":["OBJECTIVE: Patients with rheumatic diseases such as rheumatoid arthritis (RA) and lupus have increased risk of infection and are treated with medications that may increase this risk yet are also hypothesized to help treat COVID-19. We set out to understand how the COVID-19 pandemic has impacted the lives of these patients in the US. METHODS: Participants in a US-wide longitudinal observational registry responded to a supplemental COVID-19 questionnaire by email on March 25, 2020 about their symptoms, COVID-19 testing, healthcare changes, and related experiences during the prior two weeks. Analysis compared responses by diagnosis, disease activity, and new onset of symptoms. Qualitative analysis was conducted on optional free-text comment fields. RESULTS: Of the 7,061 participants invited, 530 responded, with RA the most frequent diagnosis (61%). Eleven met COVID-19 screening criteria, of which two sought testing unsuccessfully. Six others sought testing, three were successful, and all were negative. Not quite half (42%) reported a change to their care in the prior two weeks. Qualitative analysis revealed four key themes: emotions in response to the pandemic, perceptions of risks from immunosuppressive medications, protective measures to reduce risk of COVID-19 infection, and disruptions in accessing rheumatic disease medications including hydroxychloroquine. CONCLUSION: After two weeks, many with rheumatic diseases already had important changes to their healthcare, with many altering medications without professional consultation or due to hydroxychloroquine shortage. As evidence accumulates on the effectiveness of potential COVID-19 treatments, effort is needed to safeguard access to established treatments for rheumatic diseases."],"journal":"ACR Open Rheumatol","authors":["Michaud, Kaleb","Wipfler, Kristin","Shaw, Yomei","Simon, Teresa A","Cornish, Adam","England, Bryant R","Ogdie, Alexis","Katz, Patricia"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311836","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/acr2.11148","keywords":["covid-19","dmards","qualitative studies","rheumatology"],"locations":["US","US","US"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine"],"topics":["Prevention"],"weight":1,"_version_":1666138491244773377,"score":186.61882},{"pmid":32314010,"pmcid":"PMC7167494","title":"Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","text":["Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.","Rheumatol Int","Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho","32314010"],"abstract":["In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications."],"journal":"Rheumatol Int","authors":["Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314010","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s00296-020-04584-7","keywords":["covid-19","coronavirus","disease-modifying antirheumatic drugs","pneumonia","rheumatoid arthritis"],"locations":["Wuhan","China","myalgia"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine","lopinavir-ritonavir drug combination"],"topics":["Case Report"],"weight":1,"_version_":1666138493447831555,"score":173.00494},{"pmid":32112884,"pmcid":"PMC7102539","title":"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China.","text":["Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China.","BACKGROUND: Little is known about COVID-19 outside Hubei. The aim of this paper was to describe the clinical characteristics and imaging manifestations of hospitalized patients with confirmed COVID-19 infection in Wenzhou, Zhejiang, China. METHODS: In this retrospective cohort study, 149 RT-PCR confirmed positive patients were consecutively enrolled from January 17th to February 10th, 2020 in three tertiary hospitals of Wenzhou. Outcomes were followed up until Feb 15th, 2020. FINDINGS: A total of 85 patients had Hubei travel/residence history, while another 49 had contact with people from Hubei and 15 had no traceable exposure history to Hubei. Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C-reactive protein. On chest computed tomography (CT), lung segments 6 and 10 were mostly involved. A total of 287 segments presented ground glass opacity, 637 presented mixed opacity and 170 presented consolidation. Lesions were more localized in the peripheral lung with a patchy form. No significant difference was found between patients with or without Hubei exposure history. Seventeen patients had normal CT on admission of these, 12 had negative findings even10 days later. INTERPRETATION: Most patients presented with a mild infection in our study. The imaging pattern of multifocal peripheral ground glass or mixed opacity with predominance in the lower lung is highly suspicious of COVID-19 in the first week of disease onset. Nevetheless, some patients can present with a normal chest finding despite testing positive for COVID-19. FUNDING: We did not receive any fundings.","J Infect","Yang, Wenjie","Cao, Qiqi","Qin, Le","Wang, Xiaoyang","Cheng, Zenghui","Pan, Ashan","Dai, Jianyi","Sun, Qingfeng","Zhao, Fengquan","Qu, Jieming","Yan, Fuhua","32112884"],"abstract":["BACKGROUND: Little is known about COVID-19 outside Hubei. The aim of this paper was to describe the clinical characteristics and imaging manifestations of hospitalized patients with confirmed COVID-19 infection in Wenzhou, Zhejiang, China. METHODS: In this retrospective cohort study, 149 RT-PCR confirmed positive patients were consecutively enrolled from January 17th to February 10th, 2020 in three tertiary hospitals of Wenzhou. Outcomes were followed up until Feb 15th, 2020. FINDINGS: A total of 85 patients had Hubei travel/residence history, while another 49 had contact with people from Hubei and 15 had no traceable exposure history to Hubei. Fever, cough and expectoration were the most common symptoms, 14 patients had decreased oxygen saturation, 33 had leukopenia, 53 had lymphopenia, and 82 had elevated C-reactive protein. On chest computed tomography (CT), lung segments 6 and 10 were mostly involved. A total of 287 segments presented ground glass opacity, 637 presented mixed opacity and 170 presented consolidation. Lesions were more localized in the peripheral lung with a patchy form. No significant difference was found between patients with or without Hubei exposure history. Seventeen patients had normal CT on admission of these, 12 had negative findings even10 days later. INTERPRETATION: Most patients presented with a mild infection in our study. The imaging pattern of multifocal peripheral ground glass or mixed opacity with predominance in the lower lung is highly suspicious of COVID-19 in the first week of disease onset. Nevetheless, some patients can present with a normal chest finding despite testing positive for COVID-19. FUNDING: We did not receive any fundings."],"journal":"J Infect","authors":["Yang, Wenjie","Cao, Qiqi","Qin, Le","Wang, Xiaoyang","Cheng, Zenghui","Pan, Ashan","Dai, Jianyi","Sun, Qingfeng","Zhao, Fengquan","Qu, Jieming","Yan, Fuhua"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32112884","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1016/j.jinf.2020.02.016","keywords":["covid-19","ct","infection","lung","outside hubei"],"locations":["Hubei","Wenzhou","Zhejiang","China","Wenzhou","Hubei","Hubei","Hubei","Hubei","Wenzhou","Zhejiang","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666138490763476992,"score":172.27164}]}